OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2017 On 25th June 2014
JSB Market Research added new report "OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2017" in its store Uveitis is an expanding market currently dominated by corticosteroid treatment options as well as off-label immuno-suppressive and biologic drugs. Since the conventional corticosteroid treatment is only effective in 50-60% of patients a significant number of patients can be targeted with the new treatment options. While anterior uveitis patients represent the majority of patients, all but one of the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. The uveitis market is expected to grow between 2012 and 2017, due to the introduction of biologic drugs as well as a diversification of administrative routes. Market growth is created by the increase in treatment costs and will continue beyond the forecasted time period. The new treatments will target some key unmet needs but opportunities will remain for drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile. Browse Full Report @ http://www.jsbmarketresearch.com/healthcare-medical/rOpportunityAnalyzer-Uveitis-Opportunity-Analysis-and-Forecasts-to-2017-114977
Highlights Key Questions Answered - The uveitis market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the uveitis market? - The late-stage uveitis pipeline is filled with diverse molecules and routes of administration. Which drug will have a significant impact on the uveitis market. Which of these drugs will have the highest CAGR, and why? Email ID- firstname.lastname@example.org Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- The current uveitis market is dominated by corticosteroids as well as off-label immunosuppressive and biologic drugs. How will the introduction of biologic drugs change the treatment landscape once reimbursement is not a problem anymore? How will the drug treatment rates change over the next five years? What are the key drivers and barriers to this change? Key Findings - The main driver of the expansion of the uveitis market will be the introduction of biologic drugs, which will increase the market size significantly. The introduction of new ocular administration routes will strengthen the market growth further. - An additional driver for the uveitis market is the assignment of orphan drug status to several uveitis drugs. - The biggest barrier for the introduction of the more costly treatment options like biologics will be reimbursement especially in the European markets. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively. - Pipeline drugs developed by small to mid-size pharma companies represent a good opportunity for companies to enter the uveitis market and to strengthen their ophthalmology department.
Scope - Overview of uveitis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized uveitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for five years to 2017. - Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the uveitis therapeutics market. - Pipeline analysis: focus on the five late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs. - Analysis of the current and future market competition in the global uveitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. Email ID- email@example.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Develop business strategies by understanding the trends shaping and driving the global uveitis therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global uveitis therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global uveitis therapeutics market from 2012-2017. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Table of Content 2 Introduction 2.1 Catalyst 2.2 Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Important Cytokines for the Pathogenesis of Uveitis and Their Role in Emerging Treatments 3.1.2 Uveitis and Systemic Diseases 3.1.3 Prognosis and Diagnosis 3.1.4 Quality of Life 3.2 Symptoms Email ID- firstname.lastname@example.org Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
4 Epidemiology 4.1 Risk Factors and Comorbidities 4.1.1 Smoking increases the risk of uveitis and increases its complications 4.1.2 Juvenile idiopathic arthritis patients need regular ophthalmologic screenings 4.1.3 HLA-positive antigens are linked to certain types of uveitis 4.1.4 Uveitis is associated with various autoimmune, neurological, and infectious diseases 4.2 Global Trends 4.2.1 US 4.2.2 5EU 4.3 Forecast Methodology 4.3.1 Sources Used 4.3.2 Sources Not Used 4.3.3 Forecast Assumptions and Methods, Incident Cases 4.3.4 Forecast Assumptions and Methods, Prevalent Cases 4.3.5 Forecast Assumptions and Methods, Etiological and Anatomical Distribution 4.3.6 Forecast Assumptions and Methods, Course of the Disease 4.3.7 Forecast Assumptions and Methods, Disease Severity 4.4 Epidemiological Forecast for Uveitis (2012-2022) 4.4.1 Incident Cases of Uveitis 4.4.2 Age-Specific Incident Cases of Uveitis 4.4.3 Sex-Specific Incident Cases 4.4.4 Age-Standardized Incidence Rates 4.4.5 Incident Cases by Primary Anatomical Location of Inflammation 4.4.6 Incident Cases Segmented by Etiology 4.4.7 Incident Cases by Course of Disease 4.4.8 Incident Cases by Severity of Disease 4.4.9 Prevalent Cases of Uveitis 4.4.10 Age-Specific Prevalent Cases of Uveitis 4.4.11 Sex-Specific Prevalent Cases of Uveitis 4.4.12 Prevalent Cases by Primary Anatomical Location of Inflammation 4.4.13 Prevalent Cases by Etiology 4.5 Discussion 4.5.1 Epidemiological Forecast Insight 4.5.2 Limitations of the Analysis 4.5.3 Strengths of the Analysis 5 Current Treatment Options 5.1 Overview Email ID- email@example.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
5.2 Product Profiles - Major Brands 5.2.1 Retisert (Fluocinolone acetonide) 5.2.2 Ozurdex (Dexamethasone Acetate) 6 Unmet Needs Assessment and Opportunity Analysis 6.1 Overview 6.2 Unmet Needs Analysis 6.2.1 Therapy to maintain vision and control inflammation 6.2.2 Drugs with fewer adverse events 6.2.3 Increased number of approved and reimbursed treatments 6.2.4 Less frequent and more efficient treatment for anterior uveitis patients 6.2.5 Development of a non-corticosteroid ocular implant 6.2.6 Education of physicians and improved treatment guidelines 6.3 Opportunity Analysis 6.3.1 A drug that is able to maintain vision 6.3.2 A drug with an improved side effect profile 7 Research and Development Strategies 7.1 Overview 7.1.1 Uveitis as an Add-On Indication 7.1.2 Uveitis as a First Indication for a New Drug 7.1.3 Development of Ophthalmic Routes of Administration 7.2 Clinical Trial Design 8 Pipeline Assessment 8.1 Overview 8.2 Promising Drugs in Clinical Development 8.2.1 Humira (adalimumab) 8.2.2 EGP-437 (dexamethasone acetate) 8.2.3 Xoma 052 (gevokizumab) 8.2.4 DE-109 (sirolimus) 8.2.5 Medidur (fluocinolone acetonide) 8.3 Innovative Early-Stage Approaches 9 Pipeline Valuation Analysis 9.1 Clinical Benchmarks of Key Pipeline Drugs 9.2 Commercial Benchmarks of Key Pipeline Drugs 9.3 Competitive Assessment 9.4 Top-Line Five-Year Forecast Email ID- firstname.lastname@example.org Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
9.4.1 US 9.4.2 5EU 10 Appendix 10.1 Bibliography 10.2 Abbreviations 10.3 Methodology 10.4 Forecast Methodology 10.4.1 Diagnosed and Treated Uveitis Patients 10.4.2 Uveitis: Course of Disease 10.4.3 Uveitis: Severity 10.4.4 Drugs Included in Each Therapeutic Class 10.4.5 Launch and Patent Expiry Dates 10.4.6 General Pricing Assumptions 10.4.7 Individual Drug Assumptions 10.4.8 Generic Erosion 10.4.9 Pricing of Pipeline Agents 10.5 Physicians and Specialists Included in This Study 10.6 About the Authors 10.6.1 Author 10.6.2 Epidemiologist 10.6.3 Global Head of Healthcare 10.7 About Us 10.8 Disclaimer List of Tables Table 1: Anatomic Classification of Uveitis Table 2: Disease Course of Uveitis Table 3: Cytokines and Their Significance in Uveitis Table 4: Systemic Diseases Associated with Uveitis Table 5: Prognosis for Uveitis Patients Table 6: Symptoms and Ocular Comorbidities Associated with Uveitis Table 7: Diseases Most Frequently Associated with Uveitis Table 8: Distribution of Uveitis by Anatomical Location in Community and Referral Centers Table 9: Distribution of Uveitis Cases by Anatomical Location of Inflammation, Europe Table 10: IUSG/SUN Working Group Classification of Uveitis by Anatomical Location of Inflammation Table 11: SUN/IUSG Clinical Classifications of Uveitis Email ID- email@example.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 12: 6MM, Sources of Data for the Incidence and Prevalence of Uveitis in the 6MM Table 13: Italy, Uveitis Anatomical Distribution Calculation Table 14: US, Anatomical Locations of Uveitis for Incident and Prevalent Cases Table 15: 6MM, Incident Cases of Uveitis, N (Column %), Select Years, 2012-2022 Table 16: 6MM, Age-Specific Incident Cases of Uveitis, N (Row %), 2012 Table 17: 6MM, Sex-Specific Incident Cases of Uveitis, N (Row %), 2012 Table 18: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N (Row %), 2012 Table 19: 6MM, Incident Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012 Table 20: 6MM, Incident Cases of Uveitis Segmented by Etiology and Anatomical Location, N, 2012 Table 21: 6MM, Incident Cases of Uveitis by Course of Disease, N (Row %), 2012 Table 22: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012 Table 23: 6MM, Prevalent Cases of Uveitis, N (Column %), Select Years, 2012-2022 Table 24: 6MM, Age-Specific Prevalent Cases of Uveitis, N (Row %), 2012 Table 25: 6MM, Sex-Specific Prevalent Cases of Uveitis, N (Row %), 2012 Table 26: 6MM, Prevalent Cases of Uveitis by Anatomical Location of Inflammation, N (Row %), 2012 Table 27: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012 Table 28: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Anatomical Location, 2012 Table 29: Overview of the Most Common Uveitis Treatments Table 30: New Treatments for Uveitis Table 31: Product Profile - Retisert Table 32: Retisert SWOT Analysis Table 33: Product Profile - Ozurdex Table 34: Ozurdex SWOT Analysis Table 35: Overall Unmet Needs - Current Level of Attainment Table 36: Uveitis - Late Stage Pipeline, 2012 Table 37: Product Profile - Humira Table 38: Humira SWOT Analysis Table 39: EGP-437 Product Profile Table 40: EGP-437 SWOT Analysis Table 41: Xoma 052 Product Profile Table 42: Xoma 052 SWOT Analysis Table 43: DE-109 Product Profile Table 44: DE-109 SWOT Analysis Table 45: Medidur Product Profile Table 46: Medidur SWOT Analysis Email ID- firstname.lastname@example.org Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 47: Early-Stage Pipeline Products in Uveitis Table 48: Clinical Benchmarks of Pipeline Biologics Table 49: Clinical Benchmarks of Pipeline Ocular Implants Table 50: Clinical Benchmarks of Pipeline Topical Corticosteroids Table 51: Clinical Benchmark of Pipeline Ocular Injections Table 52: Commercial Benchmarks of Pipeline Ocular Implants Table 53: Commercial Benchmark of PipelineTopical Corticosteroids Table 54: Commercial Benchmark of Pipeline Ocular Injections Table 55: Top-Line Sales Forecast ($) for Uveitis, 2012-2017 Table 56: Key Events Impacting Sales for Uveitis in the US and EU, 2012-2017 Table 57: US and EU Uveitis Markets, Drivers and Barriers, 2012-2017 Table 58: Key Launch Dates Table 59: Key Patent Expiries List of Figures Figure 1: Anatomy of the Eye Figure 2: Underlying Mechanism of Autoimmune Uveitis Figure 3: US, Age Distribution of the Study Populations Compared with the US General Population Figure 4: US, Sex Ratio of the Study Populations Compared with the US General Population Figure 5: 6MM, Incident Cases of Uveitis, N, Select Years, 2012-2022 Figure 6: 6MM, Age-Specific Incident Cases of Uveitis, N, 2012 Figure 7: 6MM, Sex-Specific Incident Cases of Uveitis, N, 2012 Figure 8: 6MM, Age-Standardized Uveitis Incidence, Cases per 100,000 Population, Men and Women, 2012 Figure 9: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N, 2012 Figure 10: 6MM, Incident Cases of Uveitis by Course of Disease, N, 2012 Figure 11: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012 Figure 12: 6MM, Prevalent Cases of Uveitis, N, Select Years, 2012-2022 Figure 13: 6MM, Age-Specific Prevalent Cases of Uveitis, N, 2012 Figure 14: 6MM, Sex-Specific Prevalent Cases of Uveitis, N, 2012 Figure 15: Current Treatment of Uveitis Figure 16: Competitive Assessment of Late-Stage Pipeline Agents in Uveitis, 2012-2017 Figure 17: Global Sales for Uveitis by Country, 2012-2017
Email ID- email@example.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Related reports: Orion Corporation (ORNBV) - Financial and Strategic SWOT Analysis Review Global Top 10 Pharmaceutical Companies: Company Guide Healthcare and Medical Market Research
About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is one-stop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience. To know more on OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2017 http://www.jsbmarketresearch.com/healthcare-medical/r-OpportunityAnalyzer-UveitisOpportunity-Analysis-and-Forecasts-to-2017-114977
Email ID- firstname.lastname@example.org Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Published on Jun 25, 2014
Uveitis is an expanding market currently dominated by corticosteroid treatment options as well as off-label immuno-suppressive and biologic...